{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:30Z","timestamp":1786982190221,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2501600"],"award-info":[{"award-number":["2021YFC2501600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04163-5","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T03:48:49Z","timestamp":1737776929000},"page":"597-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma"],"prefix":"10.1007","volume":"88","author":[{"given":"Shuqing","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Balderrama-Brondani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-3106","authenticated-orcid":false,"given":"Weiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"issue":"11","key":"4163_CR1","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"T.M. Kerkhofs, R.H. Verhoeven, J.M. Van der Zwan, J. Dieleman, M.N. Kerstens, T.P. Links et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer 49(11), 2579\u20132586 (2013). https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"4163_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H.R. Haak et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476\u20131490 (2020). https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","journal-title":"Ann. Oncol."},{"issue":"11","key":"4163_CR3","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1210\/jc.2010-0803","volume":"95","author":"M Fassnacht","year":"2010","unstructured":"M. Fassnacht, S. Johanssen, W. Fenske, D. Weismann, A. Agha, F. Beuschlein et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J. Clin. Endocrinol. Metab. 95(11), 4925\u20134932 (2010). https:\/\/doi.org\/10.1210\/jc.2010-0803","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"4163_CR4","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1210\/jc.2019-00915","volume":"104","author":"JF Tierney","year":"2019","unstructured":"J.F. Tierney, S.V. Chivukula, J. Poirier, S.G. Pappas, E. Schadde, M. Hertl et al. National treatment practice for adrenocortical carcinoma: have they changed and have we made any progress? J. Clin. Endocrinol. Metab. 104(12), 5948\u20135956 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00915","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4163_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","volume":"128","author":"O Kimpel","year":"2023","unstructured":"O. Kimpel, P. Schindler, L. Schmidt-Pennington, B. Altieri, F. Megerle, H. Haak et al. Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma. Br. J. Cancer 128(4), 586\u2013593 (2023). https:\/\/doi.org\/10.1038\/s41416-022-02082-0","journal-title":"Br. J. Cancer"},{"issue":"4","key":"4163_CR6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"M. Fassnacht, O.M. Dekkers, T. Else, E. Baudin, A. Berruti, R. de Krijger et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 179(4), G1\u2013g46 (2018). https:\/\/doi.org\/10.1530\/eje-18-0608","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"4163_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky, P. Brock et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc Netw. 19(7), 839\u2013868 (2021). https:\/\/doi.org\/10.6004\/jnccn.2021.0032","journal-title":"J. Natl Compr. Canc Netw."},{"issue":"5","key":"4163_CR8","doi-asserted-by":"publisher","first-page":"R215","DOI":"10.1530\/eje-18-0027","volume":"178","author":"A Jouinot","year":"2018","unstructured":"A. Jouinot, J. Bertherat, MANAGEMENT OF ENDOCRINE DISEASE: adrenocortical carcinoma: differentiating the good from the poor prognosis tumors. Eur. J. Endocrinol. 178(5), R215\u2013r30 (2018). https:\/\/doi.org\/10.1530\/eje-18-0027","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"4163_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/jc.2013-2856","volume":"99","author":"T Else","year":"2014","unstructured":"T. Else, A.R. Williams, A. Sabolch, S. Jolly, B.S. Miller, G.D. Hammer, Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 99(2), 455\u2013461 (2014). https:\/\/doi.org\/10.1210\/jc.2013-2856","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4163_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrendo.2010.235","volume":"7","author":"M Fassnacht","year":"2011","unstructured":"M. Fassnacht, R. Lib\u00e9, M. Kroiss, B. Allolio, Adrenocortical carcinoma: a clinician\u2019s update. Nat. Rev. Endocrinol. 7(6), 323\u2013335 (2011). https:\/\/doi.org\/10.1038\/nrendo.2010.235","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"4163_CR11","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1111\/bcp.14721","volume":"87","author":"CR Corso","year":"2021","unstructured":"C.R. Corso, A. Acco, C. Bach, S.J.R. Bonatto, B.C. de Figueiredo, L.M. de Souza, Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br. J. Clin. Pharmacol. 87(7), 2698\u20132710 (2021). https:\/\/doi.org\/10.1111\/bcp.14721","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"23","key":"4163_CR12","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P.A. Conton et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356(23), 2372\u20132380 (2007). https:\/\/doi.org\/10.1056\/NEJMoa063360","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"4163_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1677\/erc-09-0190","volume":"17","author":"B W\u00e4ngberg","year":"2010","unstructured":"B. W\u00e4ngberg, A. Khorram-Manesh, S. Jansson, B. Nilsson, O. Nilsson, C.E. Jakobsson et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr. Relat. Cancer 17(1), 265\u2013272 (2010). https:\/\/doi.org\/10.1677\/erc-09-0190","journal-title":"Endocr. Relat. Cancer"},{"issue":"4","key":"4163_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"A. Berruti, S. Grisanti, A. Pulzer, M. Claps, F. Daffara, P. Loli et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 102(4), 1358\u20131365 (2017). https:\/\/doi.org\/10.1210\/jc.2016-2894","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4163_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje-18-0923","volume":"180","author":"A Calabrese","year":"2019","unstructured":"A. Calabrese, V. Basile, S. Puglisi, P. Perotti, A. Pia, L. Saba et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur. J. Endocrinol. 180(6), 387\u2013396 (2019). https:\/\/doi.org\/10.1530\/eje-18-0923","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4163_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/erc-07-0003","volume":"15","author":"A Stigliano","year":"2008","unstructured":"A. Stigliano, L. Cerquetti, M. Borro, G. Gentile, B. Bucci, S. Misiti et al. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr. Relat. Cancer 15(1), 1\u201310 (2008). https:\/\/doi.org\/10.1677\/erc-07-0003","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"4163_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1677\/erc.1.1315","volume":"15","author":"L Cerquetti","year":"2008","unstructured":"L. Cerquetti, B. Bucci, R. Marchese, S. Misiti, U. De Paula, R. Miceli et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 15(2), 623\u2013634 (2008). https:\/\/doi.org\/10.1677\/erc.1.1315","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"4163_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/cancers11111768","volume":"11","author":"L Cerquetti","year":"2019","unstructured":"L. Cerquetti, B. Bucci, G. Carpinelli, P. Lardo, A. Proietti, R. Saporito et al. Antineoplastic effect of a combined mitotane treatment\/ionizing radiation in adrenocortical carcinoma: a preclinical study. Cancers 11(11), 1768 (2019). https:\/\/doi.org\/10.3390\/cancers11111768","journal-title":"Cancers"},{"issue":"11","key":"4163_CR19","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1210\/jc.2006-1007","volume":"91","author":"M Fassnacht","year":"2006","unstructured":"M. Fassnacht, S. Hahner, B. Polat, A.C. Koschker, W. Kenn, M. Flentje et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 91(11), 4501\u20134504 (2006). https:\/\/doi.org\/10.1210\/jc.2006-1007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4163_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","volume":"92","author":"A Sabolch","year":"2015","unstructured":"A. Sabolch, T. Else, K.A. Griffith, E. Ben-Josef, A. Williams, B.S. Miller et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 92(2), 252\u2013259 (2015). https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"4163_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.ijrobp.2010.04.030","volume":"80","author":"A Sabolch","year":"2011","unstructured":"A. Sabolch, M. Feng, K. Griffith, G. Hammer, G. Doherty, E. Ben-Josef, Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 80(5), 1477\u20131484 (2011). https:\/\/doi.org\/10.1016\/j.ijrobp.2010.04.030","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"4163_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1308231","volume":"14","author":"L Wu","year":"2023","unstructured":"L. Wu, J. Chen, T. Su, L. Jiang, Y. Han, C. Zhang et al. Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma. Front. Endocrinol. 14, 1308231 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1308231","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4163_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jc.2012-2367","volume":"98","author":"MA Habra","year":"2013","unstructured":"M.A. Habra, S. Ejaz, L. Feng, P. Das, F. Deniz, E.G. Grubbs et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98(1), 192\u2013197 (2013). https:\/\/doi.org\/10.1210\/jc.2012-2367","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4163_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2683903","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"P.R. Rosenbaum, D.B. Rubin, Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am. Statistician 39(1), 33\u201338 (1985). https:\/\/doi.org\/10.2307\/2683903","journal-title":"Am. Statistician"},{"issue":"2","key":"4163_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"T. Else, A.C. Kim, A. Sabolch, V.M. Raymond, A. Kandathil, E.M. Caoili et al. Adrenocortical carcinoma. Endocr. Rev. 35(2), 282\u2013326 (2014). https:\/\/doi.org\/10.1210\/er.2013-1029","journal-title":"Endocr. Rev."},{"issue":"5","key":"4163_CR26","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"E. Kebebew, E. Reiff, Q.Y. Duh, O.H. Clark, A. McMillan, Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg. 30(5), 872\u2013878 (2006). https:\/\/doi.org\/10.1007\/s00268-005-0329-x","journal-title":"World J. Surg."},{"issue":"11","key":"4163_CR27","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/cncr.23886","volume":"113","author":"KY Bilimoria","year":"2008","unstructured":"K.Y. Bilimoria, W.T. Shen, D. Elaraj, D.J. Bentrem, D.J. Winchester, E. Kebebew et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113(11), 3130\u20133136 (2008). https:\/\/doi.org\/10.1002\/cncr.23886","journal-title":"Cancer"},{"issue":"13","key":"4163_CR28","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1002\/cncr.24331","volume":"115","author":"B Polat","year":"2009","unstructured":"B. Polat, M. Fassnacht, L. Pfreundner, M. Guckenberger, K. Bratengeier, S. Johanssen et al. Radiotherapy in adrenocortical carcinoma. Cancer 115(13), 2816\u20132823 (2009). https:\/\/doi.org\/10.1002\/cncr.24331","journal-title":"Cancer"},{"issue":"9","key":"4163_CR29","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1210\/jc.2019-00029","volume":"104","author":"LA Gharzai","year":"2019","unstructured":"L.A. Gharzai, M.D. Green, K.A. Griffith, T. Else, C.S. Mayo, E. Hesseltine et al. Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 104(9), 3743\u20133750 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00029","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4163_CR30","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1210\/jc.2018-00918","volume":"103","author":"SH Tella","year":"2018","unstructured":"S.H. Tella, A. Kommalapati, S. Yaturu, E. Kebebew, Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database. J. Clin. Endocrinol. Metab. 103(9), 3566\u20133573 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00918","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"4163_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41416-019-0412-y","volume":"120","author":"L Beaton","year":"2019","unstructured":"L. Beaton, S. Bandula, M.N. Gaze, R.A. Sharma, How rapid advances in imaging are defining the future of precision radiation oncology. Br. J. Cancer 120(8), 779\u2013790 (2019). https:\/\/doi.org\/10.1038\/s41416-019-0412-y","journal-title":"Br. J. Cancer"},{"issue":"1","key":"4163_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01533-3","volume":"15","author":"J Zhu","year":"2020","unstructured":"J. Zhu, Z. Zheng, J. Shen, X. Lian, Z. Miao, J. Shen et al. Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat. Oncol. 15(1), 118 (2020). https:\/\/doi.org\/10.1186\/s13014-020-01533-3","journal-title":"Radiat. Oncol."},{"issue":"5","key":"4163_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1590\/s1677-5538.Ibju.2017.0095","volume":"43","author":"V Srougi","year":"2017","unstructured":"V. Srougi, J. de Bessa Jr., F.Y. Tanno, A.M. Ferreira, A.O. Hoff, J.E. Bezerra et al. Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? Int. Braz. J. Urol. 43(5), 841\u2013848 (2017). https:\/\/doi.org\/10.1590\/s1677-5538.Ibju.2017.0095","journal-title":"Int. Braz. J. Urol."},{"key":"4163_CR34","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.2147\/ott.S147352","volume":"10","author":"S Wang","year":"2017","unstructured":"S. Wang, W.C. Gao, S.S. Chen, L. Bai, L. Luo, X.G. Zheng et al. Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database. Onco Targets Ther. 10, 5311\u20135315 (2017). https:\/\/doi.org\/10.2147\/ott.S147352","journal-title":"Onco Targets Ther."},{"issue":"5","key":"4163_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clgc.2021.03.009","volume":"19","author":"JJ Thomas","year":"2021","unstructured":"J.J. Thomas, J.D. Tward, Stage presentation, care patterns, treatment outcomes, and impact of radiotherapy on overall survival for adrenocortical carcinoma. Clin. Genitourin. Cancer 19(5), 417\u2013424 (2021). https:\/\/doi.org\/10.1016\/j.clgc.2021.03.009","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"4163_CR36","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.amjsurg.2020.02.043","volume":"220","author":"NJ Skertich","year":"2020","unstructured":"N.J. Skertich, J.F. Tierney, S.V. Chivukula, N.T. Babazadeh, M. Hertl, J. Poirier et al. Risk factors associated with positive resection margins in patients with adrenocortical carcinoma. Am. J. Surg. 220(4), 932\u2013937 (2020). https:\/\/doi.org\/10.1016\/j.amjsurg.2020.02.043","journal-title":"Am. J. Surg."},{"issue":"7","key":"4163_CR37","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1245\/s10434-018-6510-x","volume":"25","author":"DW Nelson","year":"2018","unstructured":"D.W. Nelson, S.C. Chang, B.C. Bandera, T.D. Fischer, R. Wollman, M. Goldfarb, Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma. Ann. Surg. Oncol. 25(7), 2060\u20132066 (2018). https:\/\/doi.org\/10.1245\/s10434-018-6510-x","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"4163_CR38","doi-asserted-by":"publisher","first-page":"791.e1","DOI":"10.1016\/j.urolonc.2021.06.019","volume":"39","author":"KB Ginsburg","year":"2021","unstructured":"K.B. Ginsburg, A.A. Chandra, J.P. Schober, E.A. Handorf, R.G. Uzzo, R.E. Greenberg et al. Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: insights from the National Cancer Database. Urol. Oncol. 39(11), 791.e1\u2013791.e7 (2021). https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.019","journal-title":"Urol. Oncol."},{"issue":"12","key":"4163_CR39","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.6004\/jnccn.2021.7035","volume":"19","author":"K Wu","year":"2021","unstructured":"K. Wu, X. Liu, Z. Liu, Y. Lu, X. Wang, X. Li, Benefit of postoperative radiotherapy for patients with nonmetastatic adrenocortical carcinoma: a population-based analysis. J. Natl Compr. Canc Netw. 19(12), 1425\u20131432 (2021). https:\/\/doi.org\/10.6004\/jnccn.2021.7035","journal-title":"J. Natl Compr. Canc Netw."},{"issue":"1","key":"4163_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1245\/s10434-015-4810-y","volume":"23","author":"N Amini","year":"2016","unstructured":"N. Amini, G.A. Margonis, Y. Kim, T.B. Tran, L.M. Postlewait, S.K. Maithel et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann. Surg. Oncol. 23(1), 126\u2013133 (2016). https:\/\/doi.org\/10.1245\/s10434-015-4810-y","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"4163_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1530\/eje-13-0519","volume":"169","author":"M Ayala-Ramirez","year":"2013","unstructured":"M. Ayala-Ramirez, S. Jasim, L. Feng, S. Ejaz, F. Deniz, N. Busaidy et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur. J. Endocrinol 169(6), 891\u2013899 (2013). https:\/\/doi.org\/10.1530\/eje-13-0519","journal-title":"Eur. J. Endocrinol"},{"issue":"6","key":"4163_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.surg.2006.07.035","volume":"140","author":"BL Paton","year":"2006","unstructured":"B.L. Paton, Y.W. Novitsky, M. Zerey, A.G. Harrell, H.J. Norton, H. Asbun et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 140(6), 914\u2013920 (2006). https:\/\/doi.org\/10.1016\/j.surg.2006.07.035. discussion 9-20","journal-title":"Surgery"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04163-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04163-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T03:47:28Z","timestamp":1747021648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04163-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["4163"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04163-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data used in this manuscript are publicly available through the SEER program and can be downloaded from the SEER database. Data obtained from local database were approved by the local ethics boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}